immune system
N |
• after tamoxifen treatment of adult mice
|
• reduced response to Tnfsf13b in vitro 2 days, and in vivo 3 and 5 days after tamoxifen treatment
• lack of BrdU incorporation after Tnfsf13b induction in vivo 3 and 5 days after tamoxifen treatment
• proliferation in response to anti-Cd40 or anti-Ighm antibody induction
|
• in mesenteric lymph nodes and Peyers patches reductions in total B cells occurred as early as days 512 post-tamoxifen treatment, with further reductions occurring through the last time point examined at day 30 post-tamoxifen
|
• in mesenteric lymph nodes and Peyers patches
|
• severe reduction
|
• modest reduction
|
• modest reduction
|
hematopoietic system
• reduced response to Tnfsf13b in vitro 2 days, and in vivo 3 and 5 days after tamoxifen treatment
• lack of BrdU incorporation after Tnfsf13b induction in vivo 3 and 5 days after tamoxifen treatment
• proliferation in response to anti-Cd40 or anti-Ighm antibody induction
|
• in mesenteric lymph nodes and Peyers patches reductions in total B cells occurred as early as days 512 post-tamoxifen treatment, with further reductions occurring through the last time point examined at day 30 post-tamoxifen
|
• in mesenteric lymph nodes and Peyers patches
|
• severe reduction
|
• modest reduction
|
• modest reduction
|
cellular
• reduced response to Tnfsf13b in vitro 2 days, and in vivo 3 and 5 days after tamoxifen treatment
• lack of BrdU incorporation after Tnfsf13b induction in vivo 3 and 5 days after tamoxifen treatment
• proliferation in response to anti-Cd40 or anti-Ighm antibody induction
|